New pill targets tough cancers in early human trial
Disease control
Ongoing
This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase: PHASE1, PHASE2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC